LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Strona główna・Stock List・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Closed

SectorHealthcare

78.92 -1.26

Buy Sell

Overview

Share price change

24h

Current

Min

78.05

Max

Key metrics
By Trading Economics
Income	18M -69M
Sales	32M 34M
EPS	-0.71
Profit margin	-201.467
Employees	253
EBITDA	18M -67M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+50.93% upside

Dividends
By Dow Jones
Next Earnings	11 sie 2026

Market Stats
By TradingEconomics
Market Cap	-523M 6.6B
Previous open	80.18
Previous close	78.92

News Sentiment

By Acuity

50%

159 / 345 Ranking in Healthcare

Kymera Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 gru 2025, 08:30 UTC

Acquisitions, Mergers, Takeovers

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

Peer Comparison

Price change

Kymera Therapeutics Inc Forecast

Price Target

By TipRanks

50.93% upside

12 Months Forecast

Average 119.07 USD 50.93%

High 140 USD

Low 100 USD

Based on 16 Wall Street analysts offering 12 month price targets forKymera Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to Kymera Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

159 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.